Founded in 2011 as a partnership of renowned academic, medical and industry leaders, the New York Genome Center (NYGC) focuses on translating genomic research into clinical solutions for serious disease. As part of this mission, NYGC is dedicated to understanding the relationship between DNA sequence variation and mechanisms for human diseases, including ALS. Funding from The Tow Foundation will support this effort by advancing the main goals of the Center for Genomics of Neurogenerative Disease at the NYGC. These goals include identifying mutations underlying neurodegenerative disease; integrating DNA sequence information with RNA sequencing data; developing a functional genomics program using mouse modes and IPS cell lines to understand the mechanistic basis of disease; create and maintain a publicly available data warehouse for ALS, DNA and RNA sequencing data; and conduct education and outreach including symposia, workshops and training.
